文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

白蛋白与生理盐水输注对脓毒症相关外周组织低灌注的对比:一项概念验证前瞻性研究

Albumin versus saline infusion for sepsis-related peripheral tissue hypoperfusion: a proof-of-concept prospective study.
PubMed 文献 · Crit Care · 2024-02-07
一句话结论在已复苏的脓毒症患者中,白蛋白输注可能较生理盐水更改善外周组织低灌注(H1毛细血管再充盈时间正常化63% vs 29%)。

这项双中心前瞻性概念验证研究纳入50例脓毒症(13例脓毒症、37例脓毒性休克)且初始复苏后毛细血管再充盈时间(CRT)>3 s的患者,由主管医生自由选择输注生理盐水500 mL或20%人血清白蛋白100 mL(15分钟内)。主要终点为1小时(H1)CRT正常化(<3 s),白蛋白组显著高于生理盐水组(63% vs 29%,P=0.02)。H1时白蛋白组指尖CRT下降幅度更大(-1.0 vs -0.2秒,P=0.04),花斑评分下降也更明显;H4时白蛋白对外周组织灌注的有益效应维持,尿量有增高趋势(1.1 vs 0.7 ml/kg/h,P=0.08),白蛋白组动脉乳酸水平显著下降(P=0.03)。作者认为,在已复苏的脓毒症患者中,白蛋白输注可能较生理盐水带来更大的组织低灌注改善。

要点

  • 纳入标准:脓毒症伴或不伴休克,且初始复苏后CRT持续>3 s;共50例(脓毒症13例、脓毒性休克37例)。
  • 干预由主管医生自由选择:生理盐水500 mL或20%人血清白蛋白100 mL,15分钟内输注。
  • 主要终点H1 CRT正常化(<3 s):白蛋白组63% vs 生理盐水组29%,P=0.02。
  • H1指尖CRT下降幅度:白蛋白组-1.0秒 vs 生理盐水组-0.2秒,P=0.04;花斑评分下降也更明显。
  • H4白蛋白组尿量有增高趋势(1.1 vs 0.7 ml/kg/h,P=0.08),动脉乳酸水平显著下降(P=0.03)。

适用人群与场景

  • 脓毒症伴或不伴休克、初始复苏后CRT>3 s的患者;共50例(脓毒症13例、脓毒性休克37例),年龄中位数68岁,男性74%。
  • 感染主要来源:呼吸道54%、腹部24%。

诊断标准与关键阈值

  • 入组条件:脓毒症伴或不伴休克,且初始复苏后CRT持续>3 s。
  • 主要终点:H1时CRT正常化,定义为CRT<3 s。

处置流程与药物剂量

  • 由主管医生自由选择输注生理盐水500 mL或20%人血清白蛋白100 mL,15分钟内输注。
  • 于输注后1小时(H1)和4小时(H4)分析全局血流动力学参数及外周组织灌注。

研究设计与关键结果

  • 双中心前瞻性概念验证研究,筛查62例,纳入50例(脓毒症13例、脓毒性休克37例),生理盐水组21例、白蛋白组29例;SOFA评分8[5-11],SAPS II 53[45-70]。
  • 基线时两组合并症、临床及生物学特征相似。
  • H1 CRT正常化(<3 s):白蛋白组63% vs 生理盐水组29%,P=0.02。
  • H1指尖CRT下降:白蛋白组-1.0[-0.3;-1.5]秒 vs 生理盐水组-0.2[-0.1;-1.1]秒,P=0.04;花斑评分下降白蛋白组也更明显。
  • H4白蛋白组外周组织灌注有益效应维持,尿量有增高趋势:白蛋白组1.1[0.5-1.8] ml/kg/h vs 生理盐水组0.7[0.5-0.9] ml/kg/h,P=0.08。
  • 动脉乳酸水平:生理盐水组H0至H4无显著变化,白蛋白组显著下降,P=0.03。

证据类型、等级与局限

  • 证据类型:双中心前瞻性概念验证研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在已复苏的脓毒症患者中,白蛋白输注可能较生理盐水带来更大的组织低灌注改善。

指南或共识出处

  • ClinicalTrials.gov标识:NCT05094856

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Albumin has potential endothelial protective effects through antioxidant and anti-inflammatory properties. However, the effect of albumin on peripheral tissue perfusion in human sepsis remains poorly known.

METHODS: Bi-centric prospective study included patients with sepsis with or without shock and prolonged CRT > 3 s despite initial resuscitation. Clinicians in charge of the patients were free to infuse either saline 500 mL or human serum albumin 20% 100 mL over 15 min. Global hemodynamic parameters as well as peripheral tissue perfusion were analyzed after 1 (H1) and 4 h (H4). The primary endpoint was CRT normalization (< 3 s) at H1.

RESULTS: 62 patients were screened, and 50 patients (13 sepsis and 37 septic shock) were included, 21 in the saline group and 29 in the albumin group. SOFA score was 8 [5-11], and SAPS II was 53 [45-70]. Median age was 68 [60-76] years with a higher proportion of men (74%). The primary sources of infection were respiratory (54%) and abdominal (24%). At baseline, comorbidities, clinical and biological characteristics were similar between groups. At H1, CRT normalization (< 3 s) was more frequent in patients receiving albumin as compared to patients treated by saline (63 vs 29%, P = 0.02). The decrease in fingertip CRT was more important in the albumin group when compared to saline group (- 1.0 [- 0.3; - 1.5] vs - 0.2 [- 0.1; - 1.1] seconds, P = 0.04) as well as decrease in mottling score. At H4, beneficial effects of albumin on peripheral tissue perfusion were maintained and urinary output trended to be higher in the albumin group (1.1 [0.5-1.8] vs 0.7 [0.5-0.9] ml/kg/h, P = 0.08). Finally, arterial lactate level did not significantly change between H0 and H4 in the saline group but significantly decreased in the albumin group (P = 0.03).

CONCLUSION: In patients with resuscitated sepsis, albumin infusion might lead to greater improvement of tissue hypoperfusion compared to saline.

CLINICALTRIALS: gov Identifier: NCT05094856.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Gabarre P, Desnos C, Morin A, et al. Albumin versus saline infusion for sepsis-related peripheral tissue hypoperfusion: a proof-of-concept prospective study. Crit Care. 2024. PMID: 38326920. doi:10.1186/s13054-024-04827-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。